BRAF and cancer: This is reminiscent of the paradoxical MAPK activation observed BRAF-selective kinase inhibitors in BRAF-mut cancer models, whereby a kinase-inhibited BRAF protein is still able to form complexes with CRAF or yet unidentified interactors and paradoxically activate MEK and ERK downstream (10, 18, 19).